A preclinical stage drug discovery company targeting chromosomal instability to treat cancer.
Chromosomal instability (CIN) is a hallmark of cancer, present in ~80% of solid tumors, and is correlated with tumor aggressiveness, therapy resistance and poor patient prognosis. Volastra is building an integrated platform to quantify and evaluate CIN using multi-omics and computer vision as the foundation for a drug discovery engine. Clinical insights, novel drug targets and drug candidates will be derived from specially engineered cell lines and patient samples using their unique approach. Volastra has multiple programs in preclinical development and has established strategic partnerships to advance their innovative therapeutic strategies to the clinic.